Show simple item record

dc.contributor.authorLohan, Paul
dc.contributor.authorMurphy, Nick
dc.contributor.authorTreacy, Oliver
dc.contributor.authorLynch, Kevin
dc.contributor.authorMorcos, Maurice
dc.contributor.authorBingling, Chen
dc.contributor.authorRyan, Aideen E.
dc.contributor.authorGriffin, Matthew D.
dc.contributor.authorRitter, Thomas
dc.date.accessioned2018-12-03T16:25:31Z
dc.date.available2018-12-03T16:25:31Z
dc.date.issued2018-11-20
dc.identifier.citationLohan, Paul, Murphy, Nick, Treacy, Oliver, Lynch, Kevin, Morcos, Maurice, Chen, Bingling, Ryan, Aideen E. , Griffin, Matthew D., Ritter, Thomas. (2018). Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. Frontiers in Immunology, 9(2666). doi: 10.3389/fimmu.2018.02666en_IE
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/10379/14667
dc.description.abstractHigh-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. In this study, a rat model of pre-existing anti-donor immunity was developed in which comeal allografts were rejected earlier than in non-pre-sensitized recipients. In this model, third-party (non-donor, non-recipient strain) allogeneic mesenchymal stromal cells (allo-MSC) were administered intravenously 7 and 1 days prior to transplantation. Rejection-free graft survival to 30 days post-transplant improved from 0 to 63.6% in MSC-treated compared to vehicle-treated control animals (p =en_IE
dc.description.sponsorshipThis study was supported by the EU FP7 Collaborative Health Project VISICORT (grant number 602470; PL, MG, and TR) and by a Science Foundation Ireland Investigator Award (grant number 12/IA/1624; NM, OT, KL, MM, BC, and TR). The authors have also received support from a Science Foundation Ireland Strategic Research Cluster Award (REMEDI, grant number 09/SRC-B1794; AER, MG, and TR), a Science Foundation Ireland Research Centers Award (CÚRAM, grant number 13/RC/2073, MG), the EU Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086; MG), an Irish Cancer Society Fellowship (grant number CRF12RYA; AR), a Science Foundation Ireland Starting Investigator Grant (grant number 15/SIRG/3456; AR), support from Galway Foundation and the European Regional Development Fund. The authors wish to acknowledge the advice, assistance and technical expertise of Ms. Aoife Duffy of the Center for Cell Manufacturing Ireland, NUI Galway and the Flow Cytometry Core Facility, NUI Galway. All flow cytometry experiments were performed in the NUI Galway Flow Cytometry Core Facility which is supported by funds from NUI Galway, Science Foundation Ireland, the Irish Government's Programme for Research in Third Level Institutions, Cycle 5 and the European Regional Development Fund.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherFrontiers Mediaen_IE
dc.relation.ispartofFrontiers In Immunologyen
dc.subjectMesenchymal stromal cellsen_IE
dc.subjectCornea transplantationen_IE
dc.subjectHigh-risken_IE
dc.subjectPre-sensitizationen_IE
dc.subjectRegulatory T cellsen_IE
dc.subjectImmunomodulationen_IE
dc.subjectThird-partyen_IE
dc.subjectREGULATORY T-CELLSen_IE
dc.subjectSTEM-CELLSen_IE
dc.subjectALLOGRAFT SURVIVALen_IE
dc.subjectMEDIATED IMMUNOSUPPRESSIONen_IE
dc.subjectGRAFT-REJECTIONen_IE
dc.subjectTHERAPYen_IE
dc.subjectTOLERANCEen_IE
dc.subjectDRUGSen_IE
dc.subjectLUNGen_IE
dc.subjectRATSen_IE
dc.titleThird-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantationen_IE
dc.typeArticleen_IE
dc.date.updated2018-12-03T16:06:32Z
dc.identifier.doi10.3389/fimmu.2018.02666
dc.local.publishedsourcehttps://doi.org/10.3389/fimmu.2018.02666en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderSeventh Framework Programmeen_IE
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderHorizon 2020en_IE
dc.contributor.funderIrish Cancer Societyen_IE
dc.contributor.funderGalway University Foundationen_IE
dc.contributor.funderEuropean Regional Development Funden_IE
dc.internal.rssid15448648
dc.local.contactThomas Ritter, School Of Medicine, Regenerative Medicine Institute, Biosciences, Dangan. 5329 Email: thomas.ritter@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORTen_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Investigator Programme/12/IA/1624/IE/Novel therapeutic approaches to improve corneal allograft survival by cell and gene therapy and insights into the mechanism of action/en_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Strategic Research Cluster/09/SRC/B1794/IE/SRC REMEDI: REMEDI-2: From Research to Human Therapy/en_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/en_IE
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROMen_IE
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Starting Investigator Research Grant (SIRG)/15/SIRG/3456/IE/'RESTRAIN' Investigation of tumour stromal interactions in metastatic colon cancer for the identification of novel immuno-therapeutic targets/en_IE
nui.item.downloads8


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record